Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Index (AUT100)
3/18/2026, 12:00:00 AM
The U.S. FDA approved Icotyde on March 18, 2026, a once-daily oral treatment for moderate-to-severe plaque psoriasis, which has a multi-billion dollar peak sales potential.
Korean Translation
2026년 3월 18일, 미국 FDA는 수십억 달러의 최고 매출 잠재력을 가진 중등도에서 중증의 판상 건선에 대한 1일 1회 경구 치료제인 이코타이드(Icotyde)를 승인함
Related Recent Events
Hewlett Packard Enterprise Co (HPE) · Other
HPE Discover Las Vegas 2026, the company's flagship annual event, is scheduled to begin, running from June 15-18. Major announcements on AI, cloud, and networking are anticipated to drive market interest scheduled.
6/15/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Fiscal Q2 2026 earnings release is expected. The company guided for revenue between $9.6 billion and $10.0 billion and non-GAAP EPS between $0.51 and $0.55. High volatility is anticipated based on historical earnings reactions expected.
6/2/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
FDA PDUFA action date for the supplemental Biologics License Application (sBLA) for a subcutaneous formulation of LEQEMBI is May 24, 2026; Medium importance is estimated due to uncertain market reaction scheduled.
5/24/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 2027 earnings release is scheduled for May 20, 2026; Medium importance is assigned as earnings typically drive 5-10% volatility, and analysts forecast an EPS of $1.74-$1.76 estimated.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Q1 2026 earnings release is scheduled. High importance estimated due to expected market volatility.
5/13/2026, 12:00:00 AM